Switching from branded to generic glatiramer acetate: two-year clinical data from the GATE trial further support the continued efficacy and tolerability of generic glatiramer acetate

被引：0
|
作者：
Cohen, J. A. [1 ]
Belova, A. [2 ]
Barkhof, F. [3 ]
Wolf, C. [4 ]
van den Tweel, E. R. W. [5 ]
Oberye, J. J. L. [5 ]
Mulder, R. [5 ]
Koper, N. P. [5 ]
Selmaj, K. [6 ]
机构：
[1] Cleveland Clin, Mellen Ctr, Cleveland, OH 44106 USA
[2] Res Inst Traumatol & Othopaedy, Funct Diagnost, Nizhnii Novgorod, Russia
[3] Vrije Univ Amsterdam Med Ctr, Radiol, Amsterdam, Netherlands
[4] Lycalis Sprl, Brussels, Belgium
[5] Synthon BV, Nijmegen, Netherlands
[6] Med Univ Lodz, Lodz, Poland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1050
引用
收藏
页码：536 / 537
页数：2
相关论文
共 40 条
  • [1] Switching from branded to generic glatiramer acetate: two-year MRI data from the GATE trial demonstrates continuous efficacy
    Barkhof, F.
    Belova, A.
    Selmaj, K.
    Wolf, C.
    van den Tweel, E. R. W.
    Oberye, J. J. L.
    Mulder, R.
    Koper, N. P.
    Cohen, J. A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 231 - 232
  • [2] Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results
    Selmaj, Krzysztof
    Barkhof, Frederik
    Belova, Anna N.
    Wolf, Christian
    van den Tweel, Evelyn R. W.
    Oberye, Janine J. L.
    Mulder, Roel
    Egging, David F.
    Koper, Norbert P.
    Cohen, Jeffrey A.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (14) : 1909 - 1917
  • [3] Tolerability and Acceptance of Switching from Brand to Generic Glatiramer Acetate in Multiple Sclerosis
    Maraffi, Isabella
    Mallucci, Giulia
    Disanto, Giulio
    Sacco, Rosaria
    Tiberti, Massimiliano
    Gobbi, Claudio
    Zecca, Chiara
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (10)
  • [4] Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis A Randomized Clinical Trial
    Cohen, Jeffrey
    Belova, Anna
    Selmaj, Krzysztof
    Wolf, Christian
    Sormani, Maria Pia
    Oberye, Janine
    van den Tweel, Evelyn
    Mulder, Roel
    Koper, Norbert
    Voortman, Gerrit
    Barkhof, Frederik
    JAMA NEUROLOGY, 2015, 72 (12) : 1433 - 1441
  • [5] Generic glatiramer acetate is equivalent to copaxone on efficacy and safety: results of the randomized double-blind GATE trial in multiple sclerosis
    Cohen, J. A.
    Belova, A.
    Selmaj, K.
    Wolf, C.
    Oberye, J. J. L.
    van den Tweel, E. R. W.
    Koper, N. P.
    Voortman, G.
    Barkhof, F.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 38 - 39
  • [6] COPTIMIZE: a two-year observational survey of patients with relapsing remitting multiple sclerosis switching to glatiramer acetate 20 mg daily
    Ziemssen, T.
    Bajenaru, O.
    Carra, A.
    de Klippel, N.
    de Sa, J.
    Edland, A.
    Frederiksen, J.
    Heinzlef, O.
    Karageorgiou, K.
    Landtblom, A. M.
    Macias Islas, M.
    Tubridy, N.
    Gilgun-Sherki, Y.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 444 - 445
  • [7] Randomised, double-blind, cross-over trial of GTR (generic glatiramer acetate) in healthy volunteers shows similar tolerability and safety to Copaxone®
    Oberye, J.
    van den Tweel, E.
    Mulder, M.
    Voortman, G.
    Hooftman, L.
    JOURNAL OF NEUROLOGY, 2012, 259 : S113 - S113
  • [8] Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice
    Meca-Lallana, Jose
    Hernandez, Luis
    Belen Caminero, Ana
    Miguel Giron, Juan
    Cano-Orgaz, Antonio
    Carcelen-Gadea, Maria
    Munoz, Delicias
    Duran-Ferreras, Eduardo
    Martin-Hernandez, Javier
    Sanchez-de la Rosa, Rainel
    EUROPEAN NEUROLOGY, 2016, 76 (1-2) : 40 - 47
  • [9] Treatment patterns following initiation of generic glatiramer acetate among patients with multiple sclerosis from two large real-world databases in the United States
    Alexander, Jessica K.
    Ariely, Rinat
    Wu, Ying
    Hulbert, Erin
    Bryant, Allison
    Su, Zhaohui
    Vardi, Michaela
    Kasturi, Jyotsna
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (08) : 1323 - 1329
  • [10] Glatiramer Acetate Depot (Etended-Release) phase IIa study in patients with relapsing remitting multiple sclerosis: safety, tolerability and efficacy (no evidence of disease activity) two-year analysis
    Flechter, S.
    Miller, A.
    Popper, L.
    Kimelman, N. Bleich
    Rubnov, S.
    Danon, U.
    Marom, E.
    Milo, R.
    Chapman, J.
    Shifrin, A.
    Gilad, R.
    Hoffmann, C.
    Karussis, D.
    Karni, A.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 1013 - 1014
1234